<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605511</url>
  </required_header>
  <id_info>
    <org_study_id>18/0217</org_study_id>
    <nct_id>NCT03605511</nct_id>
  </id_info>
  <brief_title>TTP and aHUS in Complicated Pregnancies</brief_title>
  <official_title>A Observational Study to Determine the Prevalence of Pregnancy-related Thrombotic Thrombocytopenic Purpura and Atypical Haemolytic Uraemic Syndrome in Women Affected by Specific Obstetric Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single site observational study aiming to:

      (i) Identify cases of previously undiagnosed thrombotic thrombocytopenic purpura (TTP) and
      atypical haemolytic syndrome (aHUS) in a cohort of women with complicated pregnancies (ii)
      Characterise the clinical features of these cases and (ii) Identify clinical features or
      biomarkers which may help distinguish TTP/aHUS from other complications of pregnancy such as
      preeclampsia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">March 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of TTP and aHUS in the cohort</measure>
    <time_frame>At study completion, approximately 18 months after recruitment of first patient</time_frame>
    <description>Number of new cases identified as a percentage of sample size</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Atypical Hemolytic Uremic Syndrome</condition>
  <condition>Pre-Eclampsia</condition>
  <condition>HELLP Syndrome</condition>
  <condition>Thrombocytopenia</condition>
  <condition>IUGR</condition>
  <condition>Stillbirth</condition>
  <condition>Thrombotic Microangiopathies</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ADAMTS 13, complement and angiogenic biomarkers</intervention_name>
    <description>ADAMTS 13, complement and angiogenic biomarkers</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All women receiving obstetric care at University College Hospitals London NHS Trust over
        the study period
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Women, either currently pregnant or recently postpartum, and affected by one or more of
        the following complications in the index pregnancy: (i) Preeclampsia with evidence of end
        organ damage (renal/ liver/ haematological/ neurological) or uteroplacental dysfunction
        (FGR/IUFD) (ii) HELLP syndrome (iii) Fetal growth restriction (FGR) (growth &lt;10th centile)
        that is unexplained (ie not due to infection, fetal structural anomaly, fetal chromosomal
        or pre-existing maternal medical problem) (iv) Intrauterine fetal demise (IUFD) after 20
        weeks' gestation that is unexplained (v) Unexplained new onset renal impairment (defined by
        serum creatinine &gt;85umol/L 1st trimester, or &gt;80umol/L 2nd trimester, or &gt;90 umol/L 3rd
        trimester[32]; OR an increase in serum creatinine by (i) at least 1.5 times the baseline or
        (ii) of equal or greater than 26.5umol/L (as per KDIGO criteria) (vi) Unexplained new onset
        thrombocytopenia (platelets &lt;75x10^9/L)

        Exclusion Criteria:

          -  Previous diagnosis of TTP or aHUS

          -  Known disorder of complement dysregulation

          -  Patients not wishing to participate

          -  Patients aged less than 16

          -  Patients lacking capacity to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Lucy Neave, MBBS</last_name>
    <phone>+44 203 447 9884</phone>
    <email>lucy.neave.17@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Neave, MBBS</last_name>
      <email>lucy.neave.17@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Stillbirth</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement System Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

